Selected research
Industry Research
Urological Cancer Drugs Industry Research Report 2026
Market perspective
The global Urological Cancer Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Urological Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Urological Cancer Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Urological Cancer Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Urological Cancer Drugs include Johnson & Johnson, Novartis, Pfizer, GlaxoSmithKline, AstraZeneca, Tolmar Inc, Sanofi S.A, Roche Healthcare and Ipsen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Urological Cancer Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Urological Cancer Drugs Market by Company
Johnson & Johnson
Novartis
Pfizer
GlaxoSmithKline
AstraZeneca
Tolmar Inc
Sanofi S.A
Roche Healthcare
Ipsen
Indevus Pharmaceuticals Inc
Ferring Pharmaceuticals
Dendreon Corporation
Celgene Corporation
Bristol-Myers Squibb
Astellas
Abbott Laboratories
Urological Cancer Drugs Segment by Type
Tablets
Injection
Urological Cancer Drugs Segment by Application
Bladder Cancer
Testicular Cancer
Prostate Cancer
Kidney Cancer
Others
Urological Cancer Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urological Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Urological Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urological Cancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Urological Cancer Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Urological Cancer Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Urological Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablets
- Injection
Applications
- Bladder Cancer
- Testicular Cancer
- Prostate Cancer
- Kidney Cancer
- Others
Companies covered
- Johnson & Johnson
- Novartis
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- Tolmar Inc
- Sanofi S.A
- Roche Healthcare
- Ipsen
- Indevus Pharmaceuticals Inc
- Ferring Pharmaceuticals
- Dendreon Corporation
- Celgene Corporation
- Bristol-Myers Squibb
- Astellas
- Abbott Laboratories
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Urological Cancer Drugs Market Size (2021-2032)
- 2.2.2 Global Urological Cancer Drugs Sales (2021-2032)
- 2.2.3 Global Urological Cancer Drugs Market Average Price (2021-2032)
- 2.3 Urological Cancer Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tablets
- 2.3.3 Injection
- 2.4 Urological Cancer Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Bladder Cancer
- 2.4.3 Testicular Cancer
- 2.4.4 Prostate Cancer
- 2.4.5 Kidney Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Urological Cancer Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Urological Cancer Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Urological Cancer Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Urological Cancer Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Urological Cancer Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Urological Cancer Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Urological Cancer Drugs, Product Type & Application
- 3.8 Global Manufacturers of Urological Cancer Drugs, Established Date
- 3.9 Global Urological Cancer Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Johnson & Johnson
- 4.1.1 Johnson & Johnson Company Information
- 4.1.2 Johnson & Johnson Business Overview
- 4.1.3 Johnson & Johnson Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Johnson & Johnson Urological Cancer Drugs Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Urological Cancer Drugs Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Urological Cancer Drugs Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 GlaxoSmithKline
- 4.4.1 GlaxoSmithKline Company Information
- 4.4.2 GlaxoSmithKline Business Overview
- 4.4.3 GlaxoSmithKline Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GlaxoSmithKline Urological Cancer Drugs Product Portfolio
- 4.4.5 GlaxoSmithKline Recent Developments
- 4.5 AstraZeneca
- 4.5.1 AstraZeneca Company Information
- 4.5.2 AstraZeneca Business Overview
- 4.5.3 AstraZeneca Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AstraZeneca Urological Cancer Drugs Product Portfolio
- 4.5.5 AstraZeneca Recent Developments
- 4.6 Tolmar Inc
- 4.6.1 Tolmar Inc Company Information
- 4.6.2 Tolmar Inc Business Overview
- 4.6.3 Tolmar Inc Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Tolmar Inc Urological Cancer Drugs Product Portfolio
- 4.6.5 Tolmar Inc Recent Developments
- 4.7 Sanofi S.A
- 4.7.1 Sanofi S.A Company Information
- 4.7.2 Sanofi S.A Business Overview
- 4.7.3 Sanofi S.A Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sanofi S.A Urological Cancer Drugs Product Portfolio
- 4.7.5 Sanofi S.A Recent Developments
- 4.8 Roche Healthcare
- 4.8.1 Roche Healthcare Company Information
- 4.8.2 Roche Healthcare Business Overview
- 4.8.3 Roche Healthcare Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Roche Healthcare Urological Cancer Drugs Product Portfolio
- 4.8.5 Roche Healthcare Recent Developments
- 4.9 Ipsen
- 4.9.1 Ipsen Company Information
- 4.9.2 Ipsen Business Overview
- 4.9.3 Ipsen Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Ipsen Urological Cancer Drugs Product Portfolio
- 4.9.5 Ipsen Recent Developments
- 4.10 Indevus Pharmaceuticals Inc
- 4.10.1 Indevus Pharmaceuticals Inc Company Information
- 4.10.2 Indevus Pharmaceuticals Inc Business Overview
- 4.10.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Portfolio
- 4.10.5 Indevus Pharmaceuticals Inc Recent Developments
- 4.11 Ferring Pharmaceuticals
- 4.11.1 Ferring Pharmaceuticals Company Information
- 4.11.2 Ferring Pharmaceuticals Business Overview
- 4.11.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Ferring Pharmaceuticals Urological Cancer Drugs Product Portfolio
- 4.11.5 Ferring Pharmaceuticals Recent Developments
- 4.12 Dendreon Corporation
- 4.12.1 Dendreon Corporation Company Information
- 4.12.2 Dendreon Corporation Business Overview
- 4.12.3 Dendreon Corporation Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Dendreon Corporation Urological Cancer Drugs Product Portfolio
- 4.12.5 Dendreon Corporation Recent Developments
- 4.13 Celgene Corporation
- 4.13.1 Celgene Corporation Company Information
- 4.13.2 Celgene Corporation Business Overview
- 4.13.3 Celgene Corporation Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Celgene Corporation Urological Cancer Drugs Product Portfolio
- 4.13.5 Celgene Corporation Recent Developments
- 4.14 Bristol-Myers Squibb
- 4.14.1 Bristol-Myers Squibb Company Information
- 4.14.2 Bristol-Myers Squibb Business Overview
- 4.14.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Bristol-Myers Squibb Urological Cancer Drugs Product Portfolio
- 4.14.5 Bristol-Myers Squibb Recent Developments
- 4.15 Astellas
- 4.15.1 Astellas Company Information
- 4.15.2 Astellas Business Overview
- 4.15.3 Astellas Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Astellas Urological Cancer Drugs Product Portfolio
- 4.15.5 Astellas Recent Developments
- 4.16 Abbott Laboratories
- 4.16.1 Abbott Laboratories Company Information
- 4.16.2 Abbott Laboratories Business Overview
- 4.16.3 Abbott Laboratories Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Abbott Laboratories Urological Cancer Drugs Product Portfolio
- 4.16.5 Abbott Laboratories Recent Developments
5 Global Urological Cancer Drugs Market Scenario by Region
- 5.1 Global Urological Cancer Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Urological Cancer Drugs Sales by Region: 2021-2032
- 5.2.1 Global Urological Cancer Drugs Sales by Region: 2021-2026
- 5.2.2 Global Urological Cancer Drugs Sales by Region: 2027-2032
- 5.3 Global Urological Cancer Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Urological Cancer Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Urological Cancer Drugs Revenue by Region: 2027-2032
- 5.4 North America Urological Cancer Drugs Market Facts & Figures by Country
- 5.4.1 North America Urological Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Urological Cancer Drugs Sales by Country (2021-2032)
- 5.4.3 North America Urological Cancer Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Urological Cancer Drugs Market Facts & Figures by Country
- 5.5.1 Europe Urological Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Urological Cancer Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Urological Cancer Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Urological Cancer Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Urological Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Urological Cancer Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Urological Cancer Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Urological Cancer Drugs Market Facts & Figures by Country
- 5.7.1 South America Urological Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Urological Cancer Drugs Sales by Country (2021-2032)
- 5.7.3 South America Urological Cancer Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Urological Cancer Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Urological Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Urological Cancer Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Urological Cancer Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Urological Cancer Drugs Sales by Type (2021-2032)
- 6.1.1 Global Urological Cancer Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Urological Cancer Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Urological Cancer Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Urological Cancer Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Urological Cancer Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Urological Cancer Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Urological Cancer Drugs Sales by Application (2021-2032)
- 7.1.1 Global Urological Cancer Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Urological Cancer Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Urological Cancer Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Urological Cancer Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Urological Cancer Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Urological Cancer Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Urological Cancer Drugs Value Chain Analysis
- 8.1.1 Urological Cancer Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Urological Cancer Drugs Production Mode & Process
- 8.2 Urological Cancer Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Urological Cancer Drugs Distributors
- 8.2.3 Urological Cancer Drugs Customers
9 Global Urological Cancer Drugs Analyzing Market Dynamics
- 9.1 Urological Cancer Drugs Industry Trends
- 9.2 Urological Cancer Drugs Industry Drivers
- 9.3 Urological Cancer Drugs Industry Opportunities and Challenges
- 9.4 Urological Cancer Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst